Evidence map›Paper›PMID 33669644›Full record

ArticleMetabolites2021

Untargeted Metabolomics Reveals Major Differences in the Plasma Metabolome between Colorectal Cancer and Colorectal Adenomas.

Tanja Gumpenberger, Stefanie Brezina, Pekka Keski-Rahkonen, Andreas Baierl, Nivonirina Robinot, Gernot Leeb, Nina Habermann, Dieuwertje E G Kok, Augustin Scalbert, Per-Magne Ueland and 2 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Exopolysaccharide Produced byFoods (Basel, Switzerland) · 2021
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 6 countries.

Tanja GumpenbergerInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-9319-5350
Stefanie BrezinaInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-5238-6900
Pekka Keski-RahkonenInternational Agency for Research on Cancer, 69372 Lyon, France.
Andreas BaierlDepartment of Statistics and Operations Research, University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-5329-9507
Nivonirina RobinotInternational Agency for Research on Cancer, 69372 Lyon, France.
Gernot LeebDepartment of Internal Medicine, Hospital Oberpullendorf, 7350 Oberpullendorf, Austria.
Nina HabermannDivision of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Dieuwertje E G KokDivision of Human Nutrition and Health, Wageningen University & Research, 6708 Wageningen, The Netherlands.ORCID 0000-0001-7154-8207
Augustin ScalbertInternational Agency for Research on Cancer, 69372 Lyon, France.ORCID 0000-0001-6651-6710
Per-Magne UelandBEVITAL, A/S, 5021 Bergen, Norway.
Cornelia M UlrichPopulation Sciences, Huntsman Cancer Institute, Salt Lake City, UT 84112, USA.ORCID 0000-0001-7641-059X
Andrea GsurInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-9795-1528
Centre international de recherche sur le cancer · FRMedical University of Vienna · ATBevital (Norway) · NOGerman Cancer Research Center · DEKrankenhaus Oberndorf · ATUniversity of Utah · USUniversity of Vienna · ATWageningen University & Research · NL

Funding

World Health Organization 001
6 · The paper itself

Abstract

Sporadic colorectal cancer is characterized by a multistep progression from normal epithelium to precancerous low-risk and high-risk adenomas to invasive cancer. Yet, the underlying molecular mechanisms of colorectal carcinogenesis are not completely understood. Within the "Metabolomic profiles throughout the continuum of colorectal cancer" (MetaboCCC) consortium we analyzed data generated by untargeted, mass spectrometry-based metabolomics using plasma from 88 colorectal cancer patients, 200 patients with high-risk adenomas and 200 patients with low-risk adenomas recruited within the "Colorectal Cancer Study of Austria" (CORSA). Univariate logistic regression models comparing colorectal cancer to adenomas resulted in 442 statistically significant molecular features. Metabolites discriminating colorectal cancer patients from those with adenomas in our dataset included acylcarnitines, caffeine, amino acids, glycerophospholipids, fatty acids, bilirubin, bile acids and bacterial metabolites of tryptophan. The data obtained discovers metabolite profiles reflecting metabolic differences between colorectal cancer and colorectal adenomas and delineates a potentially underlying biological interpretation.

Indexed as

adenomacolorectal cancermetabolite profilinguntargeted metabolomics

Identifiers

PMID33669644
PMCPMC7922413
OpenAlexW3130984656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.